MedPath

Comparison of two drugs levosimendan and milrinone for better outcome of coronary artery bypass grafting surgery

Phase 4
Conditions
Health Condition 1: I251- Atherosclerotic heart disease of native coronary arteryHealth Condition 2: O- Medical and Surgical
Registration Number
CTRI/2022/02/040134
Lead Sponsor
IPGMER and SSKM Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Triple vessel disease fulfilling the criteria for OPCAB

Ejection fraction (EF) 35-55%

Exclusion Criteria

I. Patientâ??s refusal

ii. Known allergy to any of the drug

iii. NYHA Grade 4

iv. Presence of haemodynamically significant arrhythmia

v. Left main coronary artery involvement

vi. Presence of hepatic / renal disease

vii. Presence of neurological disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath